Tandutinib is an antagonist of FLT3 with IC50 of 0.22 μM and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis.

FLT3-IN-1 is a potent and selective Flt3 inhibitor with IC50 of 10 nM and against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.

SB-1317 is a small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively.

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity.

ATH686 is the second-generation FLT3 inhibitor.

MRX-2843 is an orally available small-molecule inhibitor of both MERTK and FLT3.

AI-10-49 is a protein-protein interaction inhibitor that selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1 with a FRET IC50 of 0.26 μM.